Sourced: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Paradigm Biopharmaceuticals (PAR) has completed its $35 million placement to help fund its Phase 3 osteoarthritis (OA) clinical trial
  • The placement price was $1.30 per share, a 23.1 per cent discount to Paradigm’s last trading price
  • The company is aiming to develop a safe and effective treatment for sufferers of Osteoarthritis
  • Paradigm is down 5.62 per cent on the market this afternoon, selling shares for $1.60 each

Paradigm Biopharmaceuticals (PAR) has completed its $35 million placement to help fund its Phase 3 osteoarthritis (OA) clinical trial.

The placement was priced at $1.30 per share, which represents a 23.1 per cent discount to Paradigm’s last trading price of $1.69 per share.

Proceeds will not only fund its OA clinical trial, but it’ll give the company financial security throughout the trial’s span.

On Monday, Paradigm announced that it has received clear guidance from the Food and Drug Administration (FDA) regarding the primary and secondary endpoints for the trial.

CEO Paul Rennie was pleased with the placement and said it shows the confidence investors have with the company.

“The strong support shown by leading institutional investors both domestic and international, is a huge endorsement of the company and its aim of developing and commercialising safe and effective treatment for sufferers of osteoarthritis,” he said.

“The proceeds from the placement will ensure the company is fully funded through the completion of the Phase 3 trial and ensure we can be singularly focused on executing the trial and delivering outcomes for patients in this very large and growing market,” he added.

Paradigm is down 5.62 per cent on the market this afternoon, selling shares for $1.60 each at 2:46 pm AEST.

PAR by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…